ExeVir Bio is a Belgium-based company that develops single-domain antibody-based therapies that help patients ward off viral infections.
ExeVir Bio has raised $1.7M in total funding. The most recent round was Grant. The last funding was announced in June 2023.
ExeVir Bio's investors include European Investment Bank, V-Bio Ventures, VIB, UCB Ventures, Vives Louvain Technology Fund.
ExeVir Bio is headquartered in Zwijnaarde, Belgium.
ExeVir Bio is a Belgium-based company that develops single-domain antibody-based therapies that help patients ward off viral infections.
ExeVir Bio is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"ExeVir Bio — Funding & Investors." VCBacked, June 28, 2023, https://www.vcbacked.co/company/exevir-bio. Accessed September 29, 2026.
VCBacked. (2023). ExeVir Bio — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/exevir-bio
{{cite web |title=ExeVir Bio — Funding & Investors |url=https://www.vcbacked.co/company/exevir-bio |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated